Literature DB >> 9829742

Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.

H B Salvesen1, O E Iversen, L A Akslen.   

Abstract

For patients with localized endometrial carcinoma at primary operation, there is a definite need for more specific prognostic parameters to select patients for adjuvant therapy. The purpose of this study was to evaluate the applicability and prognostic significance of markers for tumor cell proliferation (S phase fraction and Ki-67 expression) among endometrial carcinoma patients, relative to the information derived from established clinicopathological variables including DNA and receptor analyses. In a prospective study of 115 patients treated for endometrial carcinoma, fresh tumor tissue was collected for assessments of ploidy, S phase fraction and hormone receptor concentrations. Ki-67 expression was assessed immunohistochemically on sections from formalin-fixed and paraffin-embedded tumor specimens. These variables were examined together with traditional clinicopathological features in univariate and multivariate (Cox proportional hazards regression model) survival analyses. The median follow-up time for the survivors was 9 years (range, 5-15), with no patient lost due to insufficient follow-up information. The expression of Ki-67 was significantly associated with International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.0004), histological type (P = 0.03), and histological grade (P = 0.0001). S phase fraction was significantly associated with histological grade (P = 0.02), whereas the association with histological type was of borderline significance (P = 0.07). In univariate analyses, survival was significantly influenced by FIGO stage (P <0.0001), histological type (P = 0.0002), histological grade (P = 0.002), ploidy (P = 0.015), S phase fraction (P = 0.017), progesterone receptor concentration (P = 0.02), and Ki-67 expression (P <0.0001). In Cox regression analysis, FIGO stage (hazard ratio, 11.7; 95% confidence interval, 4.3-32.1) and Ki-67 (hazard ratio, 8.7; 95% confidence interval, 3.0-25.2) were the only variables with independent prognostic impact. When patients whose tumors were confined to the uterus were analyzed separately, Ki-67 was the only variable with an independent prognostic importance. Ki-67 expression was superior to S phase fraction both in applicability and prognostic value. FIGO stage and Ki-67 expression were the only variables with independent prognostic impact in Cox regression analysis. Ki-67 expression is assessed on the histological specimens taken routinely, with no separate sampling technique; this should make it easy to use in a routine setting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9829742

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.

Authors:  Basil R Obeidat; Ismail I Matalka; Alia A Mohtaseb; Nabih S Al-Kaisi
Journal:  Pathol Oncol Res       Date:  2012-10-10       Impact factor: 3.201

2.  PGC1α and VDAC1 expression in endometrial cancer.

Authors:  Ofra Castro Wersäll; Lina Löfstedt; Igor Govorov; Miriam Mints; Marike Gabrielson; Maria Shoshan
Journal:  Mol Clin Oncol       Date:  2020-12-30

3.  PlexinA1 expression in gastric carcinoma and its relationship with tumor angiogenesis and proliferation.

Authors:  Xiang-Yang Zhao; Lin Chen; Yu-Hong Li; Qian Xu
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

4.  Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma.

Authors:  Judicaël Hotton; Mikaël Agopiantz; Agnès Leroux; Claire Charra-Brunaud; Béatrice Marie; Hélène Busby-Venner; Olivier Morel; Jean-Louis Guéant; Jean-Michel Vignaud; Shyue-Fang Battaglia-Hsu; Guillaume Gauchotte
Journal:  Virchows Arch       Date:  2017-12-14       Impact factor: 4.064

5.  Endometrial profile of tamoxifen and low-dose estradiol combination therapy.

Authors:  Charles E Wood; Jay R Kaplan; M Babette Fontenot; J Koudy Williams; J Mark Cline
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

6.  Impact of Metformin on Cancer Biomarkers in Non-Diabetic Cancer Patients: A Systematic Review and Meta-Analysis of Clinical Trials.

Authors:  Tahereh Farkhondeh; Alireza Amirabadizadeh; Hamed Aramjoo; Silvia Llorens; Babak Roshanravan; Farhad Saeedi; Marjan Talebi; Mehdi Shakibaei; Saeed Samarghandian
Journal:  Curr Oncol       Date:  2021-04-06       Impact factor: 3.677

Review 7.  Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.

Authors:  Yanli Zhang; Dong Zhao; Changguo Gong; Fengmei Zhang; Jing He; Wei Zhang; Yulan Zhao; Jing Sun
Journal:  World J Surg Oncol       Date:  2015-06-25       Impact factor: 2.754

8.  Overexpression of MACC1 and Its significance in human Breast Cancer Progression.

Authors:  Yongbo Huang; Huizhong Zhang; Junchao Cai; Lishan Fang; Jueheng Wu; Caisheng Ye; Xun Zhu; Mengfeng Li
Journal:  Cell Biosci       Date:  2013-03-18       Impact factor: 7.133

9.  Cancer of the endometrium: current aspects of diagnostics and treatment.

Authors:  Karsten Münstedt; Phillip Grant; Joachim Woenckhaus; Gabriele Roth; Hans-Rudolf Tinneberg
Journal:  World J Surg Oncol       Date:  2004-07-21       Impact factor: 2.754

10.  Measuring the biological effect of presurgical metformin treatment in endometrial cancer.

Authors:  V N Sivalingam; S Kitson; R McVey; C Roberts; P Pemberton; K Gilmour; S Ali; A G Renehan; H C Kitchener; E J Crosbie
Journal:  Br J Cancer       Date:  2016-01-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.